SG Americas Securities’s Kazia Therapeutics KZIA Stock Holding History

SG Americas Securities’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-280	Closed	-$59K	–	3383
2022 Q2	$59K	Sell	280 -198	-41%	-$60.8K	﹤0.01%	3242
2022 Q1	$184K	Sell	478 -204	-30%	-$72.9K	﹤0.01%	2477
2021 Q4	$288K	Sell	682 -114	-14%	-$56.9K	﹤0.01%	2462
2021 Q3	$450K	Sell	796 -92	-10%	-$45.2K	﹤0.01%	2601
2021 Q2	$438K	Buy	888 +96	+12%	+$50.6K	﹤0.01%	2001
2021 Q1	$491K	Buy	+792	New	+$414K	﹤0.01%	2030

Other funds holding KZIA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities's KZIA Position: Q3 2022 in Review

SG Americas Securities sold out of Kazia Therapeutics (KZIA) in Q3 2022, closing a stake of 280 shares — an estimated $59K sold.

SG Americas Securities first reported a position in KZIA in Q1 2021 and held it in 6 quarters. The position peaked at $491K in Q1 2021. 8 funds tracked by Wall St. Rank hold KZIA as of Q3 2022.

SG Americas Securities reported no remaining Kazia Therapeutics position as of Q3 2022 after selling out during the quarter.
SG Americas Securities sold 280 Kazia Therapeutics shares in Q3 2022, an estimated $59K.
SG Americas Securities first reported a position in Kazia Therapeutics in Q1 2021 and held it in 6 quarters.
SG Americas Securities's Kazia Therapeutics position peaked at $491K in Q1 2021.
8 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2022.

Based on SG Americas Securities's 13F filing for Q3 2022, filed 31 Oct 2022.